Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071576 | 1.00 | FAAH (0.51) | FAAHTRPV1GHSRCYP3A4CYP2C19 | |
| SCHEMBL3775772 | 0.98 | FAAH (0.48) | FAAHTRPV1GHSRCYP3A4CYP2C19 | |
| SCHEMBL3775768 | 0.98 | FAAH (0.48) | FAAHTRPV1GHSRCYP3A4CYP2C19 | |
| SCHEMBL5065679 | 0.86 | GHSR (0.46) | FAAHTRPV1GHSRCYP3A4CYP2C19 | |
| SCHEMBL2156573 | 0.86 | GHSR (0.46) | FAAHTRPV1GHSRCYP3A4CYP2C19 | |
| SCHEMBL27658921 | 0.85 | FAAH (0.49) | FAAHTRPV1GHSRCYP3A4CYP2C19 | |
| SCHEMBL772183 | 0.84 | GHSR (0.46) | FAAHTRPV1GHSRCYP3A4ALDH1A1 | |
| SCHEMBL12463926 | 0.83 | ALDH1A1 (0.47) | FAAHTRPV1CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL13476046 | 0.81 | CYP3A4 (0.49) | FAAHTRPV1CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL6268190 | 0.81 | FAAH (0.63) | FAAHTRPV1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795250-B2 | Indole derivatives as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-09-14 | — | — | US | disclosed |
| US-20090105227-A1 | Thienopyrroles As Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-04-23 | — | — | US | disclosed |
| US-20080261944-A1 | Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2008-10-23 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261944-A1 | Indole Derivatives as Antiviral Agents | IDO1, IDO2, IRF3 | FAAH 2296/4885TRPV1 4206/4885GHSR 856/4885 |
| US-20090105227-A1 | Thienopyrroles As Antiviral Agents | ZC3HAV1, HAVCR2, ZC3HAV1L | FAAH 4105/4885TRPV1 1609/4885GHSR 1348/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | FAAH 1799/4885TRPV1 4871/4885GHSR 3700/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | FAAH 1799/4885TRPV1 4871/4885GHSR 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.